ES2581774T3 - Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes - Google Patents

Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes Download PDF

Info

Publication number
ES2581774T3
ES2581774T3 ES09810643.8T ES09810643T ES2581774T3 ES 2581774 T3 ES2581774 T3 ES 2581774T3 ES 09810643 T ES09810643 T ES 09810643T ES 2581774 T3 ES2581774 T3 ES 2581774T3
Authority
ES
Spain
Prior art keywords
sample
seq
therapy
treatment
panel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09810643.8T
Other languages
English (en)
Inventor
Xilin Li
Frederic Baribaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2581774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of ES2581774T3 publication Critical patent/ES2581774T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para predecir la idoneidad de un tratamiento con una terapia de destino para un trastorno relacionado gastrointestinal en un sujeto, en el que el sujeto es un paciente que proporciona la muestra antes de la administración de la terapia, y en el que la terapia es un anticuerpo anti-TNFα, que comprende: a) preparación de una muestra de ácidos nucleicos a partir de una muestra obtenida del sujeto; b) poner en contacto la muestra con un panel de segmentos de ácido nucleico que consiste en SEQ ID NOS: 1-20 para detectar niveles de los segmentos de panel; c) la evaluación de la muestra frente a un patrón de referencia de una respuesta a la terapia para determinar los niveles relativos de expresión de todos los miembros del grupo que consta de las secuencias de nucleótidos correspondientes a SEQ ID NOS: 1-20 en comparación con el estándar de referencia; y d) correlacionar los niveles de expresión relativa de la muestra y el estándar de referencia con la idoneidad del tratamiento con la terapia de destino para el trastorno gastrointestinal relacionado.

Description

DESCRIPCIÓN
imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
Tabla 2: Clasificador de conjunto de sonda de línea de base IFX
Conjunto
de Ratio Nombre (SEQ ID NO) GenBank Acc No
10
prueba ID NR vs. R
205220_at
11,1 GPR109B (SEQ ID NO:1) NM_006018
219434_at
9,3 TREM1 (SEQ ID NO:2) NM_018643
15
230170_at 8,6 OSM (SEQ ID NO:3) A1079327
213524_s_at
7,7 G0S2 (SEQ ID NO:4) NM_015714
210773_s_at
7,1 FPRLI (SEQ ID NO:5) U81501
20
236439_at
6,5 No conocido (SEQ ID NO:6) A1733564
215671_at
6,3 PDE4B (SEQ ID NO:7) AU 144792
25
243296_at 5,1 PBEF1 (SEQ ID NO:8) AA873350
228758_at
5,0 BCL6 (SEQ ID NO:9) AW264036
232555_at
4,6 CREB5 (SEQ ID NO:10) A1689210
30
39402_at 4,3 11-1B (SEQ ID NO:11) M15330
1553297_a_at
4,3 CSF3R (SEQ ID NO:12) NM_172313
35
204924_at 4,0 TLR2 (SEQ ID NO:13) NM_003264
220088_at
3,7 C5AR1 (C5R1) (SEQ ID NM_001 736
NO:14)
40
205237_at 3,5 FCN1 (SEQ ID NO:15) NM_002003
1555643_s_at
3,5 LILRA5 (LIR9) (SEQ ID AF499918
NO:16)
45
211806_s_at 3,3 KCNJ1S (SEQ ID NO: 17) D87291
208438_s_at
2,6 FGR (SEQ ID NO:18) NM_005248
211100_x_at
2,5 LILRA1 (SEQ ID NO:19) U82278
50
215966_x_at 2,4 GK3P (GK) (SEQ ID NO:20) AA292874
55
18
imagen16
imagen17
imagen18

Claims (1)

  1. imagen1
    imagen2
ES09810643.8T 2008-08-29 2009-08-28 Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes Active ES2581774T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9296608P 2008-08-29 2008-08-29
US92966P 2008-08-29
PCT/US2009/055323 WO2010025340A2 (en) 2008-08-29 2009-08-28 Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel

Publications (1)

Publication Number Publication Date
ES2581774T3 true ES2581774T3 (es) 2016-09-07

Family

ID=41722298

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09810643.8T Active ES2581774T3 (es) 2008-08-29 2009-08-28 Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes

Country Status (12)

Country Link
US (1) US20100069256A1 (es)
EP (1) EP2329259B1 (es)
JP (1) JP5586607B2 (es)
CN (1) CN102165315B (es)
AU (1) AU2009285644B2 (es)
BR (1) BRPI0917379A2 (es)
CA (1) CA2734519C (es)
DK (1) DK2329259T3 (es)
ES (1) ES2581774T3 (es)
IL (1) IL211154A0 (es)
RU (1) RU2011111748A (es)
WO (1) WO2010025340A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943310B2 (en) * 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
WO2012154987A1 (en) * 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
MX2017004742A (es) * 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2016092045A1 (en) * 2014-12-11 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting medically refractory acute severe colitis
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
KR20240095363A (ko) 2016-05-20 2024-06-25 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
WO2017216206A1 (en) * 2016-06-14 2017-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting acute severe colitis treatment response
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
WO2020082011A1 (en) * 2018-10-19 2020-04-23 Children's Hospital Medical Center Use of mucosal transcriptomes for assessing severity of ulcerative colitis and responsiveness to treatment
CN113316647A (zh) * 2018-11-15 2021-08-27 詹森生物科技公司 用于预测对炎性肠病疗法的反应的方法和组合物
CN114015689B (zh) * 2021-10-26 2024-06-07 江苏大学 一种特异性抑制GOS2基因表达的shRNA序列及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5721098A (en) 1986-01-16 1998-02-24 The Regents Of The University Of California Comparative genomic hybridization
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
DE69330750T2 (de) 1992-03-04 2002-07-04 Univ California Vergleichende genomhybridisierung
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
AU700315B2 (en) 1993-10-28 1998-12-24 Houston Advanced Research Center Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5723320A (en) 1995-08-29 1998-03-03 Dehlinger; Peter J. Position-addressable polynucleotide arrays
US5843655A (en) 1995-09-18 1998-12-01 Affymetrix, Inc. Methods for testing oligonucleotide arrays
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
AU3568897A (en) 1996-06-07 1998-01-05 Eos Biotechnology, Inc. Immobilised linear oligonucleotide arrays
DE69720041T2 (de) 1996-11-14 2004-01-08 Affymetrix, Inc., Santa Clara Chemische amplifizierung zur synthese von musterordnungen
EP1012335A4 (en) 1997-08-15 2004-06-09 Hyseq Inc METHODS AND COMPOSITIONS FOR DETECTION OR QUANTIFICATION OF NUCLEIC ACID SPECIES
US6197503B1 (en) 1997-11-26 2001-03-06 Ut-Battelle, Llc Integrated circuit biochip microsystem containing lens
US6087102A (en) 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6087103A (en) 1998-03-04 2000-07-11 Lifespan Biosciences, Inc. Tagged ligand arrays for identifying target-ligand interactions
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6093370A (en) 1998-06-11 2000-07-25 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
US6087112A (en) 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6174684B1 (en) 1999-08-11 2001-01-16 Trustees Of The University Of Pennsylvania CYP3A4 NFSE variant and methods of use therefore
JP2004500867A (ja) 2000-06-07 2004-01-15 ベイラー　カレッジ　オブ　メディシン アレイ利用型核酸ハイブリダイゼーションのための新規な組成物および方法
US20040077020A1 (en) * 2001-11-30 2004-04-22 Mannick Elizabeth E. Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2006048291A2 (en) * 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
CA2644517A1 (en) * 2006-03-03 2007-09-13 University Of Southern California Genetic markers for predicting disease and treatment outcome
US7943310B2 (en) * 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
WO2008137383A2 (en) * 2007-04-30 2008-11-13 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel
WO2010044952A2 (en) * 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders

Also Published As

Publication number Publication date
EP2329259A2 (en) 2011-06-08
JP5586607B2 (ja) 2014-09-10
BRPI0917379A2 (pt) 2015-11-17
AU2009285644A1 (en) 2010-03-04
EP2329259B1 (en) 2016-04-20
CN102165315A (zh) 2011-08-24
EP2329259A4 (en) 2012-05-16
RU2011111748A (ru) 2012-10-10
IL211154A0 (en) 2011-04-28
CN102165315B (zh) 2014-06-18
DK2329259T3 (en) 2016-05-09
CA2734519A1 (en) 2010-03-04
US20100069256A1 (en) 2010-03-18
AU2009285644B2 (en) 2015-08-20
WO2010025340A2 (en) 2010-03-04
CA2734519C (en) 2018-11-13
WO2010025340A3 (en) 2010-04-22
JP2012501452A (ja) 2012-01-19

Similar Documents

Publication Publication Date Title
ES2581774T3 (es) Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes
Schmidt et al. Metabolomics in cancer research and emerging applications in clinical oncology
Cronin et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer
Lacroix et al. COX-2-derived prostaglandin E2 produced by pyramidal neurons contributes to neurovascular coupling in the rodent cerebral cortex
Shen et al. Rapid profiling cell cycle by flow cytometry using concurrent staining of DNA and mitotic markers
BRPI1008957B8 (pt) método para detecção simultânea de uma pluralidade de ácidos nucleicos alvo executado por um sistema de análise integrada em tempo real de ácidos nucleicos alvo
Ma et al. Multiplex detection of histone-modifying enzymes by total internal reflection fluorescence-based single-molecule detection
JP2014527168A5 (es)
Suram et al. Cytosolic phospholipase A2α and eicosanoids regulate expression of genes in macrophages involved in host defense and inflammation
JP2009534667A5 (es)
JP7374415B2 (ja) Ｐｄ－１シグナル阻害剤による疾患治療における有効性判定マーカー
Zhu et al. Extracellular glutamate-induced mTORC1 activation via the IR/IRS/PI3K/Akt pathway enhances the expansion of porcine intestinal stem cells
ES2660131T3 (es) Análisis de la expresión proteica para identificar compuestos genotóxicos
EP3947743A1 (en) Methods of diagnosing disease
JP2017503481A5 (es)
D’Lugos et al. Prior acetaminophen consumption impacts the early adaptive cellular response of human skeletal muscle to resistance exercise
Neto et al. Non-invasive classification of macrophage polarisation by 2P-FLIM and machine learning
Downs et al. Correlation of serum and dried blood spot results for quantitation of Schistosoma circulating anodic antigen: a proof of principle
Jothi et al. Metabolic variations between low-grade and high-grade gliomas—profiling by 1H NMR spectroscopy
Navaratnarajah et al. Rifampicin-Independent Interactions Between the Pregnane X Receptor Ligand Binding Domain and Peptide Fragments of Co-Activator and Co-Repressor Proteins
Liu et al. Early kinetics of procalcitonin in predicting surgical outcomes in type A aortic dissection patients
Uri et al. Bisubstrate fluorescent probes and biosensors in binding assays for HTS of protein kinase inhibitors
Tian et al. A highly sensitive and selective two-photon fluorescent probe for glutathione S-transferase detection and imaging in living cells and tissues
Liu et al. The F-techniques: advances in receptor protein studies
Tseng et al. Determination of intrinsic dissolution rate using miniaturized rotating and stationary disk systems